Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM) Share Price

Price 235.00p on 27-03-2025 at 17:30:00
Change 17.00p 7.8%
Buy 236.00p
Sell 232.00p
Buy / Sell HCM Shares
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Sell 5,822.00 at 235.00p
Day's Volume: 84,885
Last Close: 235.00p
Open: 228.00p
ISIN: KYG4672N1198
Day's Range 228.00p - 237.00p
52wk Range: 206.00p - 353.00p
Market Capitalisation: £2,009m
VWAP: 232.24706p
Shares in Issue: 855m

Sector: Medicine and Biotech

Listed In: FTSE AIM 100, FTSE AIM All-Share,

Hutchmed (HCM) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 5,822 235.00p Uncrossing Trade
 16:35:07 - 27-Mar-25
Sell* 7 235.00p Automatic Execution
 16:06:56 - 27-Mar-25
Sell* 36 235.00p Automatic Execution
 16:06:56 - 27-Mar-25
Buy* 6 235.00p Automatic Execution
 16:06:56 - 27-Mar-25
Buy* 202 235.00p Automatic Execution
 16:05:08 - 27-Mar-25
Sell* 4 232.00p SI Trade
 15:43:02 - 27-Mar-25
Sell* 15 232.00p SI Trade
 15:42:57 - 27-Mar-25
Sell* 285 233.00p Automatic Execution
 15:18:25 - 27-Mar-25
Sell* 117 233.00p Automatic Execution
 15:18:25 - 27-Mar-25
Sell* 360 233.00p Automatic Execution
 15:18:25 - 27-Mar-25
See more Hutchmed trades

Hutchmed (HCM) Share Price History

Time period:
to
Date Open High Low Close Volume
27th Mar 2025 (Thu) 228.00 237.00 228.00 235.00 84,885
26th Mar 2025 (Wed) 228.00 228.00 218.00 218.00 20,318
25th Mar 2025 (Tue) 231.00 231.00 225.00 227.00 24,426
24th Mar 2025 (Mon) 231.00 239.00 231.00 233.00 12,764
21st Mar 2025 (Fri) 241.00 242.00 227.00 227.00 157,572
20th Mar 2025 (Thu) 256.00 259.00 250.00 250.00 26,478
19th Mar 2025 (Wed) 238.00 257.00 238.00 245.00 39,148
18th Mar 2025 (Tue) 231.00 232.00 227.00 230.00 34,666
17th Mar 2025 (Mon) 231.00 236.00 231.00 231.00 19,023
14th Mar 2025 (Fri) 237.00 245.00 237.00 243.00 18,251
13th Mar 2025 (Thu) 235.00 240.00 235.00 237.00 4,749
12th Mar 2025 (Wed) 236.00 245.00 234.00 242.00 13,854
11th Mar 2025 (Tue) 235.00 243.00 235.00 240.00 162,607
10th Mar 2025 (Mon) 251.00 253.00 238.00 238.00 98,861
7th Mar 2025 (Fri) 257.00 261.00 256.00 259.00 24,350
6th Mar 2025 (Thu) 251.00 251.00 248.00 248.00 20,179
5th Mar 2025 (Wed) 257.00 260.00 255.00 259.00 10,317
4th Mar 2025 (Tue) 256.00 257.00 250.00 251.00 42,831
3rd Mar 2025 (Mon) 256.00 261.00 253.00 257.00 7,592
28th Feb 2025 (Fri) 261.00 266.00 259.00 266.00 17,397
See more Hutchmed price history

Hutchmed (HCM) Regulatory News

Date Source Headline
21st Mar 2025 10:00 am RNS-R NMPA Conditional Approval for TAZVERIK®
20th Mar 2025 9:30 am RNS Retirement of Independent Non-executive Directors
20th Mar 2025 7:00 am RNS-R HUTCHMED Highlights Savolitinib SAVANNAH Phase II
19th Mar 2025 1:45 pm RNS-R Publication of Form 20-F
19th Mar 2025 11:00 am RNS 2024 Final Results and Business Updates
19th Mar 2025 7:00 am RNS-R Phase II/III Study of Fruquintinib and Sintilimab
14th Mar 2025 9:30 am RNS Adoption of the 2025 Long Term Incentive Plan
14th Mar 2025 9:30 am RNS Vesting of awards under Long Term Incentive Plan
13th Mar 2025 9:30 am RNS Notice of Extraordinary General Meeting
6th Mar 2025 10:00 am RNS-R Completed Enrollment of Phase II Study
See more Hutchmed regulatory news

Hutchmed (HCM) Share News

IN BRIEF: Hutchmed China's Tazverik conditionally approved in China

21st Mar 2025 12:23

Hutchmed China Ltd - Hong Kong-based biopharmaceutical firm - The new drug application for Tazverik has been granted conditional approval by the National Medical Products Administration in China for the treatment of adult patients with relapsed or refractory follicular lymphoma with the EZH2 gene mutation who have received at least two prior systemic therapies. Approval was based on positive results from a phase II bridging study in China, and clinical studies conducted by Epizyme Inc, a subsidiary of Paris-based pharmaceutical firm Ipsen SA. Read More

IN BRIEF: Hutchmed highlights positive lung cancer test results

20th Mar 2025 14:31

Hutchmed China Ltd - Hong Kong-based biopharmaceutical firm - Results from the Savannah phase 2 trial showed savolitinib plus Tagrisso achieved a clinically meaningful and durable objective response rate in patients with epidermal growth factor receptor mutated non-small cell lung cancer with high levels of MET overexpression and/or amplification, whose disease progressed on treatment with first line Tagrisso. MET refers to abnormal production of a receptor tyrosine kinase, beyond its normal levels, and is associated with tumour growth and progression. Hutchmed will present new and updated data from several studies in Paris at the European Lung Cancer Congress, which will take place between next week Wednesday and March 29. Tagrisso is a drug made by AstraZeneca PLC. Read More

Hutchmed China celebrates kidney cancer treatment; swings to loss

19th Mar 2025 12:08

(Alliance News) - Hutchmed China Ltd on Wednesday hailed results of a clinical trial evaluating its kidney cancer treatment in China, while it reported an annual revenue dive. Read More

UK earnings, trading statements calendar - next 7 days

12th Mar 2025 14:31

Read More

IN BRIEF: Hutchmed lung cancer treatment Orpathys approved in China

14th Jan 2025 12:07

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Says its lung cancer treatment Orpathys has received full approval in China for adult patients. It has been developed in collaboration with AstraZeneca PLC, with Hutchmed leading in China and AZ leading outside of China. The drug was approved by the China National Medical Products Administration for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer. The approval was based on data from the confirmatory phase 3B clinical trial. Read More

See more Hutchmed news
FTSE 100 Latest
Value8,666.12
Change-23.47

Login to your account

Forgot Password?

Not Registered